2020
Estimation of Excess Deaths Associated With the COVID-19 Pandemic in the United States, March to May 2020
Weinberger DM, Chen J, Cohen T, Crawford FW, Mostashari F, Olson D, Pitzer VE, Reich NG, Russi M, Simonsen L, Watkins A, Viboud C. Estimation of Excess Deaths Associated With the COVID-19 Pandemic in the United States, March to May 2020. JAMA Internal Medicine 2020, 180: 1336-1344. PMID: 32609310, PMCID: PMC7330834, DOI: 10.1001/jamainternmed.2020.3391.Peer-Reviewed Original ResearchConceptsCOVID-19Excess deathsOfficial COVID-19 deathsCoronavirus disease 2019Entire US populationPublic health impactCOVID-19 diagnostic testsCOVID-19 burdenCOVID-19 deathsCause deathReported deathsMortality burdenObservational studyDisease 2019Influenza activityMAIN OUTCOMEDeath AssociatedWeekly deathsTotal deathsUS deathsMore deathsDeath recordsUS populationHealth StatisticsTest availabilityTransmission Modeling with Regression Adjustment for Analyzing Household-based Studies of Infectious Disease: Application to Tuberculosis.
Crawford FW, Marx FM, Zelner J, Cohen T. Transmission Modeling with Regression Adjustment for Analyzing Household-based Studies of Infectious Disease: Application to Tuberculosis. Epidemiology 2020, 31: 238-247. PMID: 31764276, PMCID: PMC7718772, DOI: 10.1097/ede.0000000000001143.Peer-Reviewed Original ResearchConceptsSusceptible household contactsHousehold contactsTB casesBacillus Calmette-Guérin (BCG) vaccinationInfected household contactsIsoniazid preventive therapyActive tuberculosis casesCulture-positive casesRisk of diseaseCohort studyMicrobiological confirmationPreventive therapyTuberculosis casesRisk factorsInfection resultsAdult contactsInfection riskInfectious diseasesLogistic regressionRate of transmissionTransmissible diseasesDiseaseIndividual-level characteristicsHigher hazardDisease susceptibility
2019
Cost‐effectiveness of expanding the capacity of opioid agonist treatment in Ukraine: dynamic modeling analysis
Morozova O, Crawford FW, Cohen T, Paltiel AD, Altice FL. Cost‐effectiveness of expanding the capacity of opioid agonist treatment in Ukraine: dynamic modeling analysis. Addiction 2019, 115: 437-450. PMID: 31478285, PMCID: PMC7015766, DOI: 10.1111/add.14797.Peer-Reviewed Original ResearchConceptsOpioid agonist treatmentOpioid use disorderOAT coverageAgonist treatmentGross domestic productOpioid use initiationOpioid addiction epidemicOAT accessHIV epidemicUse disordersAddiction epidemicCapita gross domestic productPay thresholdsTreatment demandUse initiationAddiction treatmentIncremental costBaseline capacityTreatmentPotential peer effectsDomestic productTreatment spilloversEpidemicPeer effectsCoverage levels
2018
Risk ratios for contagious outcomes
Morozova O, Cohen T, Crawford FW. Risk ratios for contagious outcomes. Journal Of The Royal Society Interface 2018, 15: 20170696. PMID: 29343627, PMCID: PMC5805970, DOI: 10.1098/rsif.2017.0696.Peer-Reviewed Original Research
2016
Benefits of continuous isoniazid preventive therapy may outweigh resistance risks in a declining tuberculosis/HIV coepidemic
Kunkel A, Crawford FW, Shepherd J, Cohen T. Benefits of continuous isoniazid preventive therapy may outweigh resistance risks in a declining tuberculosis/HIV coepidemic. AIDS 2016, 30: 2715-2723. PMID: 27782966, PMCID: PMC5089846, DOI: 10.1097/qad.0000000000001235.Peer-Reviewed Original ResearchConceptsContinuous isoniazid preventive therapyIsoniazid preventive therapyIsoniazid-resistant tuberculosisTB epidemicPreventive therapyEffective TB treatmentLatent TB infectionTB drug resistanceTransmission dynamic modelTB infectionMortality benefitTB treatmentHIV controlHIV incidenceTB incidenceTB transmissionCase findingDrug resistanceIncidenceTuberculosisInitial benefitPLHIVHIVTherapyEpidemicBenefits of continuous isoniazid preventive therapy may outweigh resistance risks in a declining TB/HIV co-epidemic.
Kunkel A, Crawford FW, Shepherd J, Cohen T. Benefits of continuous isoniazid preventive therapy may outweigh resistance risks in a declining TB/HIV co-epidemic. AIDS (London, England) 2016 PMID: 27536981.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply